Perioperative Apalutamide and ADT Reduce Recurrence Risk in High-Risk Prostate Cancer
Clinical data showed that adding apalutamide and androgen-deprivation therapy before and after surgery reduced the risk of recurrence or death by 62% compared with prostatectomy alone in high-risk localized prostate cancer patients, as reported.
-
Key Clinical Takeaways:
- The PROTEUS trial evaluated 6 months of neoadjuvant and adjuvant apalutamide alongside androgen-deprivation therapy in 2,100 patients.
- Patients with low-tier high-risk disease experience high cure rates with standard monotherapies, showing minimal event-rate differences from added systemic treatments.
- Selection protocols prioritize higher-volume, high-grade disease to maximize the clinical benefit of perioperative androgen receptor pathway inhibitors.
High-grade cancers impact clinical trial results
Localized prostate cancer spans a wide biological spectrum of aggressiveness and genomic risk, according to Gleave, a distinguished professor in the department of urologic sciences at the University of British Columbia in Vancouver, Canada, who spoke to CancerNetwork. Unless clinical trials include more patients with higher-volume, high-grade cancers, the event rates in lower-tier high-risk subgroups stay too low to show meaningful differences from standard care, Gleave explained to CancerNetwork.
“You have to recognize that localized prostate cancer is a wide spectrum of aggressiveness, histologically as well as genomically, from low to intermediate to high risk,” Gleave told CancerNetwork.
Patients with low-volume Gleason grade group 4 cancer and a prostate-specific antigen level of 8 ng/mL fall into a low-tier high-risk category and do not benefit from the PROTEUS regimen, Gleave told CancerNetwork. In contrast, trials such as PROTEUS and the biomarker-directed Genomic Umbrella Neoadjuvant Study require multiple positive cores with Gleason pattern 4 or 5 and/or a prostate-specific antigen level above 20 ng/mL.
“If a patient has a low-volume Gleason [grade group] 4 cancer with a prostate-specific antigen [PSA] level of 8 [ng/mL], even though he is high risk, he is low-tier high risk and does not benefit from the PROTEUS regimen,” Gleave told CancerNetwork.

Systemic treatment reduces death or metastasis risk
Gleave said that 70% of control-arm patients undergoing prostatectomy alone relapsed by 3 years, as reported by MedPage Today.
Introducing active systemic treatment aims to induce tumor regression, improve resectability, address subclinical metastases, and delay subsequent metastatic progression, according to MedPage Today. Mary-Ellen Taplin of Dana-Farber Cancer Institute in Boston discussed findings at the European Society for Medical Oncology congress, noting a 51% lower risk of death or metastasis assessed by prostate-specific membrane antigen PET or conventional imaging, according to MedPage Today.
“At ASCO 2026 in the plenary, the PROTEUS main study was presented, which was a very large, 2,100-patient study, which looked at the effect of 6 months of neoadjuvant apalutamide and ADT compared to placebo and ADT, followed by prostatectomy,” Taplin told MedPage Today.
Managing adverse events
Adverse effects associated with apalutamide include fatigue, hot flashes, hypertension, and rash, though these are generally managed easily in clinical practice, according to MedPage Today.
Taplin said that the associated rash is immune-mediated rather than an allergic antibiotic-type reaction, allowing patients to continue treatment with a dose reduction or short interruption, as MedPage Today reported. Clinical data also showed no increase in surgical complications when combining the regimen with prostatectomy, as MedPage Today reported.
“The rash with apalutamide is different than a rash say with antibiotics,” Taplin told MedPage Today. “It’s less of an allergic type rash and more immune-mediated where patients can continue the drug with a dose reduction or a short interruption.”
Curative opportunities in advanced cohorts
Patient selection remains central to integrating surgery and systemic therapy, requiring physicians to identify individuals with elevated recurrence risk who retain an opportunity for curative surgery, according to MedPage Today. Gleave emphasized that surgical judgment dictates whether a patient is an appropriate candidate for resection, noting that systemic therapy does not render an unresectable tumor resectable, according to CancerNetwork.

“From a clinical judgment and patient selection perspective, the sweet spot is higher-volume, high-grade disease,” Gleave told CancerNetwork. “However, if you are considering surgery, these patients still have to fall within the clinical judgment of resectability and appropriateness for surgery. You are not going to make somebody who is unresectable resectable with systemic therapy, and that is where surgical judgment comes in.”
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Related reading